| 1 |
34165774 | MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. | 2021 Oct |
6 |
| 2 |
29741513 | Myelofibrosis: clinicopathologic features, prognosis, and management. | 2018 Feb |
1 |
| 3 |
30498775 | Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. | 2018 Nov |
1 |
| 4 |
28232234 | The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. | 2017 Jun |
2 |
| 5 |
29074595 | Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. | 2017 Oct 26 |
1 |
| 6 |
26303809 | Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. | 2016 Jun |
1 |